Preclinical and translational research to discover potentially effective antifibrotic therapies in systemic sclerosis

Current Opinion in Rheumatology

Volumn 25, Issue 6, 2013, Pages 679-685

  Jordan, Suzana ^a   Chung, James ^b   Distler, Oliver ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b AMGEN INC   (United States)

Author keywords

biomarker driven proof of concept studies; Drug development; Systemic sclerosis

Indexed keywords

ANTIFIBROTIC AGENT; BIOLOGICAL MARKER; BLEOMYCIN; TAMOXIFEN;

CLINICAL TRIAL; DRUG EXPOSURE; DRUG MECHANISM; DRUG TARGETING; HUMAN; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SYSTEMIC SCLEROSIS; TRANSLATIONAL RESEARCH;

ANIMALS; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; DRUG DESIGN; HUMANS; MICE; MOLECULAR TARGETED THERAPY; SCLERODERMA, SYSTEMIC; TRANSLATIONAL MEDICAL RESEARCH; TREATMENT OUTCOME;

EID: 84885324490     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/01.bor.0000434598.51526.0e     Document Type: Review

References (15)

1. Walker UA, Tyndall A, Czirjak L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: A report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 2007; 66:754-763
2. Kahaleh MB, Sherer GK, LeRoy EC. Endothelial injury in scleroderma. J Exp Med 1979; 149:1326-1335
3. Beyer C, Schett G, Distler O, Distler JH. Animal models of systemic sclerosis: Prospects and limitations. Arthritis Rheum 2010; 62:2831-2844
4. Fleischmajer R, Perlish JS, Reeves Jr. Cellular infiltrates in scleroderma skin. Arthritis Rheum 1977; 20:975-984
5. Maurer B, Distler O. Emerging targeted therapies in scleroderma lung and skin fibrosis. Best Pract Res Clin Rheumatol 2011; 25:843-858
6. Beyer C, Distler O, Distler JH. Innovative antifibrotic therapies in systemic sclerosis. Curr Opin Rheumatol 2012; 24:274-280
7. Dees C, Akhmetshina A, Zerr P, et al. Platelet-derived serotonin links vascular disease and tissue fibrosis. J Exp Med 2011; 208:961-972
8. Akhmetshina A, Venalis P, Dees C, et al. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum 2009; 60:219-224
9. Severino ME, Dubose RF, Patterson SD. A strategic view on the use of pharmacodynamic biomarkers in early clinical drug development. IDrugs 2006; 9:849-853
10. .Zieba A, Grannas K, Soderberg O, et al. Molecular tools for companion diagnostics. N Biotechnol 2012; 29:634-640
11. Paul SM, Mytelka DS, Dunwiddie CT, et al. How to improve R&D productivity: The pharmaceutical industry's grand challenge. Nat Rev Drug Discov 2010; 9:203-214
12. Castro SV, Jimenez SA. Biomarkers in systemic sclerosis. Biomark Med 2010; 4:133-147
13. .Lafyatis R. Application of biomarkers to clinical trials in systemic sclerosis. Curr Rheumatol Rep 2012; 14:47-55
14. .Love D, Stratton E, Stocum M. Best practices for companion diagnostic and therapeutic development: Translating between the stakeholders. N Biotechnol 2012; 29:689-694
15. Farina G, Lafyatis D, Lemaire R, Lafyatis R. A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2010; 62:580-588